BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Waidmann O. Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther. 2018;18:905-910. [PMID: 29995439 DOI: 10.1080/14712598.2018.1499722] [Cited by in Crossref: 42] [Cited by in F6Publishing: 56] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Shi F, Zheng S, Zhao M, Pan Z, Xiong L, Zheng L. Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment. Front Oncol 2022;12:896662. [DOI: 10.3389/fonc.2022.896662] [Reference Citation Analysis]
2 Wei X, Zhang DQ, Zhang LZ, Liu W, Liu P, Xu Y. Role of STING signaling pathway in liver diseases. Shijie Huaren Xiaohua Zazhi 2022; 30(15): 674-679 [DOI: 10.11569/wcjd.v30.i15.674] [Reference Citation Analysis]
3 Gnocchi D, Kurzyk A, Mintrone A, Lentini G, Sabbà C, Mazzocca A. Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma. Biochimie 2022:S0300-9084(22)00192-4. [PMID: 35952946 DOI: 10.1016/j.biochi.2022.07.016] [Reference Citation Analysis]
4 Ma J, Jin J, Lu H, Zhang J, Li Y, Cai X. Exonuclease 1 is a Potential Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma. Front Mol Biosci 2022;9:889414. [DOI: 10.3389/fmolb.2022.889414] [Reference Citation Analysis]
5 Sheng J, Zhang J, Wang L, Tano V, Tang J, Wang X, Wu J, Song J, Zhao Y, Rong J, Cheng F, Wang J, Shen Y, Wen L, He J, Zhang H, Li T, Zhang Q, Bai X, Lu Z, Liang T. Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny. Gut 2022;71:1176-91. [PMID: 34253573 DOI: 10.1136/gutjnl-2021-324339] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
6 Li G, Tian Y, Gao Z, Ma X, Ren C. Identification of Immune-Related Markers in Hepatocellular Carcinoma Based on Gene Co-expression Network. Biochem Genet 2022. [PMID: 35633444 DOI: 10.1007/s10528-022-10235-2] [Reference Citation Analysis]
7 Wang Z, Rehman AU, Qin X, Zhu C, Wu S, Bukhari I. PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-18. [DOI: 10.1155/2022/7545666] [Reference Citation Analysis]
8 Cai J, Chen Z, Zhang Y, Wang J, Zhang Z, Wu J, Mao J, Zuo X. CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m6A modification in hepatocellular carcinoma. Mol Ther Oncolytics 2022;24:755-71. [PMID: 35317519 DOI: 10.1016/j.omto.2022.02.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Hosseinzadeh F, Ai J, Hajifathali A, Muhammadnejad S, Ebrahimi-Barough S, Seyhoun I, Komeili Movahed T, Shirian S, Hosseinzadeh F, Ahmadpour S, Alijani M, Verdi J. The effects of Sorafenib and Natural killer cell co-injection in combinational treatment of hepatocellular carcinoma; an in vivo approach. Pharmacol Rep 2022. [PMID: 35089543 DOI: 10.1007/s43440-021-00335-y] [Reference Citation Analysis]
10 Shang BB, Chen J, Wang ZG, Liu H. Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma. PeerJ 2021;9:e12315. [PMID: 34754620 DOI: 10.7717/peerj.12315] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
11 Meng M, Wu YC. Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma. J Immunol Res 2021;2021:1782728. [PMID: 34527749 DOI: 10.1155/2021/1782728] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Xie S, Hou X, Yang W, Shi W, Yang X, Duan S, Mo F, Liu A, Wang W, Lu X. Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects. Int J Nanomedicine 2021;16:6017-34. [PMID: 34511903 DOI: 10.2147/IJN.S317220] [Reference Citation Analysis]
13 Chen B, Rao X, Wang X, Luo Z, Wang J, Sheng S, Liu Y, Zhang N, Jin S, Chen H, Sun C, Xu T, Du Y. cGAS-STING Signaling Pathway and Liver Disease: From Basic Research to Clinical Practice. Front Pharmacol 2021;12:719644. [PMID: 34483930 DOI: 10.3389/fphar.2021.719644] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
14 Liu H, Cheng J, Xu H, Wan Z. Lidocaine has antitumor effect on hepatocellular carcinoma via the circ_DYNC1H1/miR-520a-3p/USP14 axis. Open Life Sci 2021;16:766-80. [PMID: 34435133 DOI: 10.1515/biol-2021-0072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Temraz S, Nassar F, Kreidieh F, Mukherji D, Shamseddine A, Nasr R. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. Int J Mol Sci 2021;22:7800. [PMID: 34360566 DOI: 10.3390/ijms22157800] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
16 Gnocchi D, Cavalluzzi MM, Mangiatordi GF, Rizzi R, Tortorella C, Spennacchio M, Lentini G, Altomare A, Sabbà C, Mazzocca A. Xanthenylacetic Acid Derivatives Effectively Target Lysophosphatidic Acid Receptor 6 to Inhibit Hepatocellular Carcinoma Cell Growth. ChemMedChem 2021;16:2121-9. [PMID: 33831272 DOI: 10.1002/cmdc.202100032] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
17 Bao JH, Shang HT, Hao CF, Liu JJ, Han SW, Zhang DL, Li ZL. Prognostic value of IL-26 level in hepatocellular carcinoma tissue in postoperative patients with hepatitis B related hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2021; 29(10): 511-516 [DOI: 10.11569/wcjd.v29.i10.511] [Reference Citation Analysis]
18 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
19 Baby J, Devan AR, Kumar AR, Gorantla JN, Nair B, Aishwarya TS, Nath LR. Cogent role of flavonoids as key orchestrators of chemoprevention of hepatocellular carcinoma: A review. J Food Biochem 2021;45:e13761. [PMID: 34028054 DOI: 10.1111/jfbc.13761] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Li L, Xia S, Shi X, Chen X, Shang D. The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma. Sci Rep 2021;11:10728. [PMID: 34021184 DOI: 10.1038/s41598-021-89747-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Gnocchi D, Castellaneta F, Cesari G, Fiore G, Sabbà C, Mazzocca A. Treatment of liver cancer cells with ethyl acetate extract of Crithmum maritimum permits reducing sorafenib dose and toxicity maintaining its efficacy. J Pharm Pharmacol 2021:rgab070. [PMID: 34014301 DOI: 10.1093/jpp/rgab070] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
22 Ou D, Tseng S, Kempson IM, Hsu C, Yang P, Liao Z. Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti‐PD1 in Liver Cancer. Adv Therap 2021;4:2100048. [DOI: 10.1002/adtp.202100048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Yu L, Huang N, Sun H, Yang X, Fu Y, Lang Q, Wang J, Ge L. Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma. J Immunother 2021;44:106-13. [PMID: 33239522 DOI: 10.1097/CJI.0000000000000349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Chen J, Ding Y, Huang F, Lan R, Wang Z, Huang W, Chen R, Wu B, Fu L, Yang Y, Liu J, Hong J, Zhang W, Zhang L. Irradiated whole-cell vaccine suppresses hepatocellular carcinoma growth in mice via Th9 cells. Oncol Lett 2021;21:409. [PMID: 33841570 DOI: 10.3892/ol.2021.12670] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Gnocchi D, Del Coco L, Girelli CR, Castellaneta F, Cesari G, Sabbà C, Fanizzi FP, Mazzocca A. 1H-NMR metabolomics reveals a multitarget action of Crithmum maritimum ethyl acetate extract in inhibiting hepatocellular carcinoma cell growth. Sci Rep 2021;11:1259. [PMID: 33441568 DOI: 10.1038/s41598-020-78867-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
26 Du X, Zhang Y. Integrated Analysis of Immunity- and Ferroptosis-Related Biomarker Signatures to Improve the Prognosis Prediction of Hepatocellular Carcinoma. Front Genet 2020;11:614888. [PMID: 33391356 DOI: 10.3389/fgene.2020.614888] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
27 Zhang J, Yang G, Li Q, Xie F. Increased fibrillarin expression is associated with tumor progression and an unfavorable prognosis in hepatocellular carcinoma. Oncol Lett 2021;21:92. [PMID: 33376525 DOI: 10.3892/ol.2020.12353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
28 Zhu Q, Pan QZ, Zhong AL, Hu H, Zhao JJ, Tang Y, Hu WM, Li M, Weng DS, Chen MY, Ma G, Xia JC. Annexin A3 upregulates the infiltrated neutrophil-lymphocyte ratio to remodel the immune microenvironment in hepatocellular carcinoma. Int Immunopharmacol 2020;89:107139. [PMID: 33191179 DOI: 10.1016/j.intimp.2020.107139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
29 Li Y, Deng G, Zhang H, Qi Y, Gao L, Tan Y, Hu P, Wang Y, Liu B, Chen Q. Weighted gene correlation network analysis identifies microenvironment-related genes signature as prognostic candidate for Grade II/III glioma. Aging (Albany NY) 2020;12:22122-38. [PMID: 33186124 DOI: 10.18632/aging.104075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Hu B, Yang XB, Sang XT. Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients. Int Immunopharmacol 2021;90:107164. [PMID: 33172741 DOI: 10.1016/j.intimp.2020.107164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Tseng HC, Xiong W, Badeti S, Yang Y, Ma M, Liu T, Ramos CA, Dotti G, Fritzky L, Jiang JG, Yi Q, Guarrera J, Zong WX, Liu C, Liu D. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun 2020;11:4810. [PMID: 32968061 DOI: 10.1038/s41467-020-18444-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
32 Pu J, Tan C, Shao Z, Wu X, Zhang Y, Xu Z, Wang J, Tang Q, Wei H. Long Noncoding RNA PART1 Promotes Hepatocellular Carcinoma Progression via Targeting miR-590-3p/HMGB2 Axis. Onco Targets Ther 2020;13:9203-11. [PMID: 32982307 DOI: 10.2147/OTT.S259962] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
33 Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci 2020;21:E6757. [PMID: 32942580 DOI: 10.3390/ijms21186757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
34 Yao M, Sai W, Zheng W, Wang L, Dong Z, Yao D. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Curr Med Chem 2020;27:3290-301. [PMID: 31232234 DOI: 10.2174/0929867326666190624161158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
35 Shen Q, Hu G, Wu J, Lv L. A new clinical prognostic nomogram for liver cancer based on immune score. PLoS One 2020;15:e0236622. [PMID: 32730361 DOI: 10.1371/journal.pone.0236622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zeng Z, Yang B, Liao ZY. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma. Oncol Lett 2020;20:45. [PMID: 32802167 DOI: 10.3892/ol.2020.11909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
37 Kang JH, Li MJ, Luan PP, Jiang DK, Chen YW, Xu X, Yu Q, Xu YW, Su Q, Peng WH, Jian WX. NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL-6/JAK2/STAT3 pathway activation. Cell Biol Int 2020;44:2053-64. [PMID: 32584509 DOI: 10.1002/cbin.11414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Zhang PF, Gao C, Huang XY, Lu JC, Guo XJ, Shi GM, Cai JB, Ke AW. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Mol Cancer 2020;19:110. [PMID: 32593303 DOI: 10.1186/s12943-020-01222-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 124] [Article Influence: 21.5] [Reference Citation Analysis]
39 Hu B, Yang XB, Sang XT. Development of an immune-related prognostic index associated with hepatocellular carcinoma. Aging (Albany NY) 2020;12:5010-30. [PMID: 32191631 DOI: 10.18632/aging.102926] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
40 Deng H, Kan A, Lyu N, Mu L, Han Y, Liu L, Zhang Y, Duan Y, Liao S, Li S, Xie Q, Gao T, Li Y, Zhang Z, Zhao M. Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer 2020;9:338-57. [PMID: 32647635 DOI: 10.1159/000505695] [Cited by in Crossref: 16] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
41 Wen Q, Han T, Wang Z, Jiang S. Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape. Oncol Lett. 2020;19:2595-2601. [PMID: 32218809 DOI: 10.3892/ol.2020.11369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
42 Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Letters 2020;470:8-17. [DOI: 10.1016/j.canlet.2019.12.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 86] [Article Influence: 16.5] [Reference Citation Analysis]
43 Shuwen H, Xi Y, Quan Q, Yin J, Miao D. Can small nucleolar RNA be a novel molecular target for hepatocellular carcinoma? Gene 2020;733:144384. [PMID: 31978508 DOI: 10.1016/j.gene.2020.144384] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
44 Liao Y. Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma. Genes Dis 2020;7:291-8. [PMID: 32884983 DOI: 10.1016/j.gendis.2019.12.014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Zhou A, Tang L, Zeng S, Lei Y, Yang S, Tang B. Gut microbiota: A new piece in understanding hepatocarcinogenesis. Cancer Lett 2020;474:15-22. [PMID: 31917160 DOI: 10.1016/j.canlet.2020.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
46 Gnocchi D, Kapoor S, Nitti P, Cavalluzzi MM, Lentini G, Denora N, Sabbà C, Mazzocca A. Novel lysophosphatidic acid receptor 6 antagonists inhibit hepatocellular carcinoma growth through affecting mitochondrial function. J Mol Med (Berl) 2020;98:179-91. [PMID: 31863151 DOI: 10.1007/s00109-019-01862-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
47 Gnocchi D, Cesari G, Calabrese GJ, Capone R, Sabbà C, Mazzocca A. Inhibition of Hepatocellular Carcinoma Growth by Ethyl Acetate Extracts of Apulian Brassica oleracea L. and Crithmum maritimum L. Plant Foods Hum Nutr 2020;75:33-40. [DOI: 10.1007/s11130-019-00781-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
48 Carrion-martin L, Orcajo Rincón J, Rotger A, Gonzalez-leyte M, Márquez Pérez L, Echenagusia M, Matilla A. Radioembolization in liver tumors. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2019;38:370-81. [DOI: 10.1016/j.remnie.2019.06.005] [Reference Citation Analysis]
49 Fan J, Zhang J, Huang S, Li P. lncRNA OSER1-AS1 acts as a ceRNA to promote tumorigenesis in hepatocellular carcinoma by regulating miR-372-3p/Rab23 axis. Biochem Biophys Res Commun 2020;521:196-203. [PMID: 31635804 DOI: 10.1016/j.bbrc.2019.10.105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
50 Zhang RY, Wei D, Liu ZK, Yong YL, Wei W, Zhang ZY, Lv JJ, Zhang Z, Chen ZN, Bian H. Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy. Front Cell Dev Biol 2019;7:233. [PMID: 31681766 DOI: 10.3389/fcell.2019.00233] [Cited by in Crossref: 14] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
51 Yang X, Yao B, Niu Y, Chen T, Mo H, Wang L, Guo C, Yao D. Hypoxia-induced lncRNA EIF3J-AS1 accelerates hepatocellular carcinoma progression via targeting miR-122–5p/CTNND2 axis. Biochemical and Biophysical Research Communications 2019;518:239-45. [DOI: 10.1016/j.bbrc.2019.08.039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 7.7] [Reference Citation Analysis]
52 Yang X, Sun L, Wang L, Yao B, Mo H, Yang W. LncRNA SNHG7 accelerates the proliferation, migration and invasion of hepatocellular carcinoma cells via regulating miR-122-5p and RPL4. Biomedicine & Pharmacotherapy 2019;118:109386. [DOI: 10.1016/j.biopha.2019.109386] [Cited by in Crossref: 20] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
53 Liu X, Hu J, Song X, Utpatel K, Zhang Y, Wang P, Lu X, Zhang J, Xu M, Su T, Che L, Wang J, Evert M, Calvisi DF, Chen X. Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E930. [PMID: 31277283 DOI: 10.3390/cancers11070930] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
54 Jing L, Ruan Z, Sun H, Li Q, Han L, Huang L, Yu S, Wang Y, Guo H, Jiao M. Epithelial-mesenchymal transition induced cancer-stem-cell-like characteristics in hepatocellular carcinoma. J Cell Physiol 2019;234:18448-58. [PMID: 30908631 DOI: 10.1002/jcp.28480] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
55 Liese J, Hinrichs TM, Lange M, Fulda S. Cotreatment with sorafenib and oleanolic acid induces reactive oxygen species-dependent and mitochondrial-mediated apoptotic cell death in hepatocellular carcinoma cells. Anti-Cancer Drugs 2019;30:209-17. [DOI: 10.1097/cad.0000000000000750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
56 Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, Cheung TT, Ng KK, Chok SH, Chan AC, Dai WC, Wong FC, Luk MY, Leung TW, Lo CM. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surg Oncol. 2019;28:228-235. [PMID: 30851906 DOI: 10.1016/j.suronc.2019.01.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]